chr6-143942155-G-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001317162.2(PLAGL1):c.661C>A(p.Leu221Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000031 in 1,614,218 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001317162.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PLAGL1 | NM_001317162.2 | c.661C>A | p.Leu221Ile | missense_variant | 8/8 | ENST00000674357.1 | NP_001304091.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PLAGL1 | ENST00000674357.1 | c.661C>A | p.Leu221Ile | missense_variant | 8/8 | NM_001317162.2 | ENSP00000501459 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152206Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000191 AC: 48AN: 251476Hom.: 0 AF XY: 0.000184 AC XY: 25AN XY: 135912
GnomAD4 exome AF: 0.0000287 AC: 42AN: 1461894Hom.: 0 Cov.: 32 AF XY: 0.0000344 AC XY: 25AN XY: 727248
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152324Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74488
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 15, 2023 | The c.661C>A (p.L221I) alteration is located in exon 7 (coding exon 2) of the PLAGL1 gene. This alteration results from a C to A substitution at nucleotide position 661, causing the leucine (L) at amino acid position 221 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at